Supply chains are being diversified and regionalized to mitigate global disruptions, with significant investments in US ...

The biopharmaceutical industry has traditionally focused on developing blockbuster drugs. However, over the past several years, a new era of drug development has unfolded. Personalized medicine and ...

After the U.S. tariff imposition, policymakers must diversify boldly, reform swiftly, and secure India’s pharma supremacy ...

Traws Pharma, Inc. (TRAW) has disclosed a new risk, in the Corporate Activity and Growth category. The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc.’s future ...

With the business potentially at an important milestone, we thought we'd take a closer look at UroGen Pharma Ltd.'s (NASDAQ:URGN) future prospects. UroGen Pharma Ltd. engages in the development and ...

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and pharma reps. As with everyone, pharma reps were at a ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Our data show that global pharma M&A is becoming more selective and strategically targeted. While North America remains the ...

Access to new-age medicines for obesity and diabetes is crucial for the Indian pharmaceutical industry's growth. Combined with AI tools, this will support accessibility and affordability. India aims ...

Based in Port Washington, Wis., Pharma-C-Wipes offers a variety of consumer products that include adult care, OTC and first aid. But the company has undergone some changes. AH: Innovation is a part of ...

Lumos Pharma (NASDAQ:LUMO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

Why is it that one of the biggest bottlenecks in getting advanced drug therapies and vaccines to patients who need them most is not an issue with the funding, or the research, or a lack of ...